UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.18
-0.08 (-0.71%)
Apr 29, 2025, 10:34 AM EDT - Market open
UroGen Pharma Employees
UroGen Pharma had 235 employees as of December 31, 2024. The number of employees increased by 34 or 16.92% compared to the previous year.
Employees
235
Change (1Y)
34
Growth (1Y)
16.92%
Revenue / Employee
$384,672
Profits / Employee
-$539,889
Market Cap
515.33M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
URGN News
- 20 hours ago - UroGen Pharma Touts Four-Year Response With Urothelial Cancer Drug Study, Highlights Potential For Bladder Cancer Candidates - Benzinga
- 1 day ago - OLYMPUS Long-Term Follow-Up Study Reports Nearly Four-Year Duration of Response in Subset of Patients with Low-Grade Upper Tract Urothelial Cancer Who Achieved a Complete Response to Initial JELMYTO Treatment - Business Wire
- 1 day ago - New Patient-Reported Outcomes from UGN-102 Clinical Trials Show the Investigational Treatment Did Not Adversely Affect Functionality, Symptom Burden, and Quality of Life in Patients with LG-IR-NMIBC - Business Wire
- 1 day ago - New Long-Term Follow-Up Data from OPTIMA II Study of UGN-102 Demonstrates Median Duration of Response of Two Years in Patients with LG-IR-NMIBC - Business Wire
- 2 days ago - UroGen Announces Updated 18-Month Duration of Response (DOR) of 80.6% from the Phase 3 ENVISION Trial of UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC) - Business Wire
- 3 days ago - UroGen Pharma Announces Encouraging Results from a Phase 1 Dose-Escalation Study Evaluating UGN-301 in Non-Muscle Invasive Bladder Cancer - Business Wire
- 15 days ago - UroGen Announces Data Presentations at the American Urological Association 2025 Annual Meeting Highlighting Emerging Evidence Supporting Our Portfolio for Urothelial Cancers - Business Wire
- 17 days ago - UroGen: June 13 PDUFA For Potential Bladder Cancer Blockbuster Sets Up Strong Buy - Seeking Alpha